SecBot SecBot

MANE

Veradermics, Inc
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001827635 Biotech & Drug Discovery
$137.51 −1.27 (−0.92%)
Oct 26 4:00 PM ET · prev $138.78
Market cap
$5.8B
Mid cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$171.00
+24% · range $135.00–204.00
Since first trade
+264.3%
from $37.75 · Feb 4
30 days
+19.6%
from $115.00
Range since listing
$37.03–138.78
−1% from high · low Feb 9
Avg volume 20D
857.8K
Oct 8 spike 3.49M
Short interest
4.24M
≈10.2% of shares · +3.4%
Days to cover
4.7
at average volume
Insider net
-$58.3M
4 buyers · 4 sellers · since Feb 5
New fund stakes
4
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/8
Strongest BULLISH Veradermics announced positive topline Phase 3 data for VDPHL01, an oral extended-release minoxidil, in male…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders bought $44.9M. 4 insiders sold $103.1M.

  • InstitutionsBULLISH

    Q2 2026: 26 added (4 new), 8 trimmed or exited. Largest new: Maverick Capital $97.1M, Frontier Capital Management $31.3M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Median target $171.00 (+24%).

  • EstimatesRISING

    Current-quarter EPS estimate −$0.642 → −$0.616 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.4% to 4.24M shares. 4.7 days to cover, ≈10.2% of shares.

  • TrendUPTREND

    23% above its 50-day average. New closing high $138.78 on Oct 23.

Who's buying

13F· Q2 2026
4
new positions
0
exits
$156.7M
in new stakes
FundMoveSharesValue
FMR LLCADD3,204,981$394.0M
BlackRock, Inc.DOUBLED1,593,791$195.9M
D. E. Shaw & Co., Inc.DOUBLED1,013,643$124.6M
MAVERICK CAPITAL LTDNEW789,980$97.1M
JENNISON ASSOCIATES LLCDOUBLED748,678$92.0M
UBS Group AGADD670,727$82.5M
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM549,706$67.6M
STATE STREET CORPDOUBLED544,369$66.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is inside the target range. Median implies +24%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 22, 2026B. Riley Securities
MAINTAIN
MAINTAINBuy
Oct 19, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Oct 19, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 16, 2026Citigroup
MAINTAIN
MAINTAINBuy
Jul 15, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 15, 2026B. Riley Securities
INITIATE
INITIATEBuy

Insider ledger

Form 4
$44.9M
bought · 4 insiders
$103.1M
sold · 4 insiders
DateInsiderTypeValue
Sep 1, 2026
Hollander David
Chief R&D Officer
AWARD9,650 sh
Sep 1, 2026
Hollander David
Chief R&D Officer
AWARD19,300 sh
Aug 20, 2026
MONTANOVA CAPITAL, LLC
Director
EXERCISE149,000 sh
Aug 20, 2026
MONTANOVA CAPITAL, LLC
Director
EXERCISE151,000 sh
Aug 20, 2026
MONTANOVA CAPITAL, LLC
Director
EXERCISE149,000 sh
Aug 20, 2026
MONTANOVA CAPITAL, LLC
Director
EXERCISE151,000 sh
Aug 19, 2026
MONTANOVA CAPITAL, LLC
Director
SELL$74.1M
Aug 19, 2026
MONTANOVA CAPITAL, LLC
Director
SELL$6.4M

Earnings setup

Estimates
−$0.62
EPS estimate, this quarter
+4%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.62-$0.74–-$0.51-4.2%$0.00
Next Q-$0.63-$0.81–-$0.45-3.9%$0.00
Current FY-$2.87-$3.12–-$2.61+0.2%$0.00
Next FY🔒 Fresh data, subscribers only
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent comments
r/stockmarket15h ago
Fresh comment, for subscribers
All social signals and their track records

Short side

FINRA· Sep 30, 2026
4,244,476
shares short
+3.4%
vs prior settlement
4.7
days to cover
≈10.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Veradermics announced positive topline Phase 3 data for VDPHL01, an oral extended-release minoxidil, in male pattern…
8-K — Impact 7/10
Oct 13, 2026 SEC
JPMorgan Chase & Co. filed a Schedule 13G disclosing a 5.6% passive stake in Veradermics, Inc. as of September 30…
SC 13G — Impact 4/10
Sep 9, 2026 Clinical trial readout
T-90d Trial Readout: VDPHL01 (Phase 3)
Trial: Safety and Efficacy of VDPHL01 in Males With AGA Sponsor: Veradermics, Inc. Phase: Phase 3 |
Sep 1, 2026 Insider
Hollander David was granted 9,650 shares
Chief R&D Officer
Sep 1, 2026 Insider
Hollander David was granted 19,300 shares
Chief R&D Officer
Aug 21, 2026 SEC
A significant insider selling cluster at Veradermics (MANE) saw CEO Reid Waldman, CTO Timothy Durso, and two directors…
CLUSTER — Impact 5/10
Aug 20, 2026 Insider
MONTANOVA CAPITAL, LLC acquired via exercise 149,000 shares
Director
Jun 30, 2026 Inst.
FMR LLC — ADD
3,204,981 shares ($394.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 9, 2026
Trial readout
T-90d Trial Readout: VDPHL01 (Phase 3)
Trial: Safety and Efficacy of VDPHL01 in Males With AGA Sponsor: Veradermics, Inc. Phase: Phase 3 | Status: ACTIVE_NOT_RECRUITING Conditions…
Jul 31, 2026
Short interest
Short Interest: MANE up 22% to 4.8M shares
Settlement 2026-07-31 | Days to cover: 6.92 | ≈11.54% of shares outstanding (est.)
Jun 30, 2026
Short interest
Short Interest: MANE up 53% to 3.8M shares
Settlement 2026-06-30 | Days to cover: 3.55 | ≈9.12% of shares outstanding (est.)
May 19, 2026
Trial readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA Sponsor: Veradermics, Inc. Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING…
May 14, 2026
Trial readout
T-90d Trial Readout: VDPHL01 (Phase 2)
Trial: Safety and Efficacy of VDPHL01 in Males and Females With AGA Sponsor: Veradermics, Inc. Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING…

SecBot reports

13 filings · 4 bullish · 2 bearish · 7 neutral
All MANE filing & press-release reports (13)